Grant GrossMendelsohn LLC Sells 14,331 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Grant GrossMendelsohn LLC cut its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 26.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,299 shares of the company’s stock after selling 14,331 shares during the quarter. Tarsus Pharmaceuticals comprises about 1.1% of Grant GrossMendelsohn LLC’s holdings, making the stock its 27th largest position. Grant GrossMendelsohn LLC’s holdings in Tarsus Pharmaceuticals were worth $2,176,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TARS. Canada Pension Plan Investment Board purchased a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth about $114,000. FMR LLC boosted its position in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the period. SG Americas Securities LLC lifted its stake in Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after purchasing an additional 3,379 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Tarsus Pharmaceuticals by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares during the period. Finally, Dark Forest Capital Management LP purchased a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $202,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on TARS shares. The Goldman Sachs Group increased their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $46.52 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The business’s fifty day simple moving average is $51.01 and its 200 day simple moving average is $38.14. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.14.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.